Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 12/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | UBASH3B | Q8TF42 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8688581 | 0.84 | GABRP (0.50) | KMT2AMEN1ALDH1A1MET | |
| SCHEMBL97230 | 0.80 | DAO (0.38) | KMT2AMEN1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL8686631 | 0.79 | MAPK14 (0.37) | KMT2AMEN1GAA | |
| SCHEMBL1248860 | 0.75 | GABRP (0.45) | KMT2AALDH1A1 | |
| SCHEMBL8688041 | 0.73 | GABRP (0.50) | ALDH1A1METLMNAMAPK1 | |
| SCHEMBL1247536 | 0.71 | ALOX15 (0.45) | KMT2AMEN1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL8685203 | 0.70 | HAT1 (0.46) | ALDH1A1 | |
| SCHEMBL8687819 | 0.70 | HAT1 (0.46) | METMAPK1 | |
| SCHEMBL8685987 | 0.70 | IGF1R (0.42) | — | |
| SCHEMBL8690729 | 0.70 | GABRP (0.42) | KDM4EHSD17B10MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-2426128-A1 | Carbostyril compound | Otsuka Pharmaceutical Co., Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2010-10-14 | — | — | US | disclosed |
| US-7777038-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20070179173-A1 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| EP-1797082-A1 | CARBOSTYRIL COMPOUND | Otsuka Pharmaceutical Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006035954-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179173-A1 | Carbostyril compound | GTF2F1, F3, GTF2F2 | KMT2A 2732/4885MEN1 3912/4885KDM4E 3919/4885 |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | GTF2F1, F3, GTF2F2 | KMT2A 2732/4885MEN1 3912/4885KDM4E 3919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.